A monoreactive NOTA (1,4,7-triazacyclononane-1,4,7-triacetic acid) derived prochelator (1-(1-carboxy-3-carbo-tert-butoxypropyl)-4,7-(carbo-tert-butoxymethyl)-1,4,7-triazacyclononane (NODAGA(tBu) 3 )) was synthesized in five steps with an overall yield of 21%. It is useful for the coupling to the N-terminus of peptides on solid phase and in solution; it was coupled to [Tyr 3 ]-octreotide (TOC) on solid phase, and the resulting peptide, NODAGA-Tyr 3
INTRODUCTION
Peptides are important regulators of growth and cellular functions in normal tissue but also in tumors. Tumors often overexpress receptors for different regulatory peptides. Certain types of tumors also respond to the growth inhibiting or growth promoting signals of certain peptides. This effect has become important in the treatment of some tumors in man. An important example are analogues of SRIF 1 (somatostatin release inhibiting factor) which are being used in the treatment of symptomatic neuroendocrine tumors and in acromegaly (1) . A development of the last 10 years or so has been the use of radiolabeled versions of regulatory peptide analogues in the in vivo localization of tumors (2) (3) (4) (5) (6) (7) (8) . Of paramount importance is the DTPA-derivatized somatostatin analogue octreotide labeled with [ 111 In] which is commercially available under the trade name OctreoScan (9, 10) . As this type of peptide-chelate conjugates show very rapid blood clearance and diffusion into different tissues, the use of short-lived positron emitters becomes feasible. We have introduced a few strategies that use [ 68 Ga], a 68 min half-life-generator-produced metallic positron emitter coupled to somatostatin analogues (11) (12) (13) . Whereas the use of the bifunctional chelator desferrioxamine-B (DFO) led to a radiopeptide which showed very good tumor targeting and visualization in a tumorbearing rat model, the same conjugate was not very successful in patients because of a slow blood clearance (14) . Ga]-DOTATOC the radioactivities in the kidneys were 8.5, 7.5, 4, and 2.5% ID/g at the same time points (11) .
The reason for these differences are not fully understood yet. The metal ion dependence may stem from structural differences within the coordination environment. The X-ray crystal structures of the model peptides Ga III -DOTA-D-PheNH 2 and Y III (In III , manuscript in preparation)-DOTA-D-PheNH 2 showed remarkable differences. In the Ga III complex, DOTA adopts a cis-pseudooctahedral geometry with a folded macrocyclic unit (2424 conformation) ( Figure 1 ). The equatorial plane is formed by two transannular nitrogens of the macrocyclic ring and the oxygens of the corresponding carboxylate groups. The axial positions are occupied by the remaining two ring nitrogens. Two potential coordination sites of the chelator are free, namely one carboxylate group and the amide carboxy oxygen (11) . This structural feature may contribute to the somewhat more efficient kidney clearance, and the latter leads to a spacer function between chelate and bioactive peptide ( Figure 1 ). This may consequently introduce less steric strain and improve receptor binding affinity and concomitantly tumor uptake in vivo. Unlike the Ga III -octreotide in the rat pancreas tumor cell line AR4-2J and a corresponding nude mice tumor model. NOTA was used because of the known high stability of the Ga III -NOTA and In III -NOTA complexes which makes any interference and false interpretation of biological and pharmacological data due to a potential transchelation chemistry rather unlikely.
The interest in peptide chelator conjugates for labeling with gallium radionuclides comes from their desirable physical properties (17, 18) . Three gallium radionuclides exist with decay characteristics that are suitable for γ-scintigraphy, PET imaging, and receptor-mediated radiotherapy:
68 Ga is a 68 min half-life-generatorproduced positron emitter which is of interest because of the 280 d half-life of the parent 68 Ge. This gives the generator a long half-life of more than 1 year and allows PET imaging at institutions without on-site cyclotron.
67
Ga has a half-life of 78.3 h and decays via electron capture with 3 γ-emissions at 93 keV (38%), 185 keV (24%), and 300 keV (16%) which are useful for planar scintigraphy and single photon emission tomography (SPET). In addition, 67 Ga is also a reasonably efficient Auger-emitter for use in internal radiotherapy if the vectors used to bring the radionuclide to the tumor cell are being internalized and the radionuclide comes close to the nucleus.
66
Ga again is a positron emitter with an attractive intermediate half-life of 9.5 h which is of current interest because of its longer half-life, more suitable to the pharmacokinetics of a variety of biomolecules (19, 20) . It is cyclotron-produced and emits positrons with an abundance of 56% and E mean ) 1.7 MeV.
EXPERIMENTAL SECTION
Materials and Methods. General Methods. All chemicals were obtained from commercial sources and used without further purification. (Fluka) . Electrospray ionization (ESI) mass spectroscopy was carried out with a Finnigan SSQ 7000 spectrometer or fast atom bombardment (FAB) mass spectroscopy with a VG 70SE spectrometer. Analytical and semipreparative HPLC was performed on a HewlettPackard 1050 HPLC system with a multiwavelength detector and a flow-through Berthold LB 506 Cl γ-detector with a Macherey-Nagel Nucleosil 120 C 18 column and preparative HPLC on a Metrohm HPLC system LCCaDI 22-14 with a Macherey-Nagel VP 250/21 Nucleosil 100-5 C 18 column. Quantitative γ-counting was performed on a COBRA 5003 γ-system well counter from Packard Instrument.
1 H and 13 C NMR was performed with either a Brucker spectrometer at 360/99 MHz or a Varian VXR 400 at 400/101 MHz. Chemical shifts reported are relative to trimethylsilane (TMS). Solidphase peptide synthesis was performed on a semiautomatic peptide synthesizer commercially available from Rink Combichem (Bubendorf, Switzerland). The cell culture medium was Dulbecco's minimal essential medium (DMEM) from GibcoBRL. DOTA-Tyr 3 -octreotide (DOTATOC) was synthesized as described before (11) .
Synthesis. Starting from the commercially available glutamic acid 5-benzyl ester, R-bromoglutaric acid diester (2) (Scheme 1) was synthesized in two steps as described before (21) .
1-(1-Carbobenzyloxy-3-carbo-tert-butoxypropyl)-1,4,7-triazacyclononane (3). A solution of 513 mg (1.44 mmol) of R-bromoglutaric acid 1-tert-butyl ester 5-benzyl ester (2) in 20 mL of chloroform was added over a period of 3 h to a solution of 557 mg (4.31 mmol) of 1,4,7 triazacyclononane in 20 mL of chloroform. The mixture was stirred over 3 d at room temperature and concentrated to a brown oil. The crude product was purified by column chromatography with silica gel 60 (5 × 20 cm; eluents: 250 mL of ethanol/ammonia 95:5; 300 mL of chloroform/ethanol/ammonia 7:3:0.5). Yield: 404 mg (69.2%) of a colorless oil. Unreacted 1,4,7-triazacyclononane was recovered and can be reused after distillation. 1 
1-(1-Carboxy-3-carbo-tert-butoxypropyl)-4,7-(carbotert-butoxymethyl)-1,4,7-triazacyclononane (NODA-GA(tBu) 3 ) (6).
A 150 mg (0.237 mmol) of 1-(1-carbobenzyloxy-3-carbo-tert-butoxypropyl)-4,7-(carbo-tertbutoxymethyl)-1,4,7-triazacyclononane (5) was dissolved in 20 mL of 2-propanol and 50 mg 10% Pd/C suspended in 0.5 mL of H 2 O was added. The mixture was treated by bubbling hydrogen through the solution over 18 h, filtered over Celite, and evaporated to dryness. The residue was chromatographed on silica gel 60 (2-propanol/ammonia 95:5) to obtain 85 mg (66%) of a yellow oil. 1 4 -Lys(Boc) 5 -Thr(tBu) 6 -Cys(Acm) 7 Thr(tBu) 8 -ol (7) was assembled on a trityl chloride resin (TCP, Pepchem, Tü bingen, Germany) using standard Fmoc (9-fluorenylmethoxycarbonyl) strategy (22) Ga III complex was synthesized according to the methods previously described (11, 16) . A mixture of 500 µg (0.34 µmol) (8) , cooled to room temperature, and purified over a SepPak C 18 cartridge preconditioned with 10 mL of ethanol and 10 mL of water. The cartridge was eluted with 10 mL of 0.4 M sodium acetate (pH 5) followed by 3 mL of methanol resulting in 400 µg (76%) of Ga-NODAGATOC after evaporation of the methanol.
). In-NODAGATOC (10) was synthesized as (9) 3 ) was prepared in the same way, using Ga(III) nitrate nonahydrate. In a modification of this protocol, acetate buffer was replaced by HEPES (150 µL, 0.1 M, pH 5.8). The final labeling solution had a pH 2.5. This protocol gave yields >95% at a specific activity of 40 GBq/µmol -1 . Subsequently radiolabeled peptides were purified utilizing a SepPak C 18 cartridge preconditioned with 10 mL of methanol and 10 mL of water; the cartridge was eluted with 3 mL of water, followed by 2 mL of ethanol, to afford the very pure radioligand with a specific activity g15 GBq µmol -1 . A quality control was performed by HPLC (eluents: A ) 0.1% TFA in water and B ) acetonitrile; gradient: 0-30 min, 55% A, 30-36 min, 100% B, 36-40 min, 95% A).
Metal/Ligand Stability Studies. The chemical stability of the radiometal complexes [
67 Ga]-and [ 111 In]-NODAGATOC was studied by measuring the rate of exchange of the radiometal in the presence of 10 5 molar excess of DTPA at pH 5. Solutions were stored at 37°C, and at periods up to 10 days aliquots were removed and analyzed by HPLC using the gradient described above.
Serum Stability. To 3 mL of fresh human serum, previously equilibrated in a 5% CO 2 (95% air) environment at 37°C, was added 5 µCi of the [
67 Ga]-NODA-GATOC standard solution. The mixture was incubated in a 5% CO 2 , 37°C environment. At appropriate periods of time (0, 30 min, 1, and 4 h), 100 µL aliquots (in triplicate) were removed and treated with 200 µL of ethanol. Samples were then cooled (4°C) and centrifuged for 15 min at 500g and 4°C to precipitate serum proteins. One hundred microliters of supernatant was removed for activity counting in a γ well-counter. The sediment was washed twice with 1 mL of ethanol and counted. The activity in supernatant was compared with the activity in the pellet to give the percent peptide not bound to proteins.
The peptide structure in the supernatant was checked by HPLC using the equipment mentioned above.
Receptor Autoradiography and Binding Affinity. Determination of peptide conjugate concentrations and receptor autoradiography was described previously (16) . Concentrations of peptides were determined spectrophotometrically using 280 ) 6800 M -1 cm -1
. IC 50 values using autoradiographic methods were determined as described (16) .
In brief, cells stably transfected with sst1-sst5 were kindly provided by Drs. T. Reisine and G. Singh (University of Pennsylvania, Philadelphia, PA). They were washed twice with and scraped into ice-cold 0.05 M TrisHCl (pH 7.4), collected by centrifugation, and homogenized using a rotor/strator slash system (Polytron, Kinematica Inc., Littau, Switzerland) in the same buffer. After centrifugation at 120 g for 5 min at 4°C, the supernatant was collected and centrifuged again at 48.000 g for 30 min at 4°C. The resulting pellet was resuspended in ice-cold Tris buffer, transferred into a microfuge tube, and centrifuged at 20.000 g for 15 min at 4°C. After withdrawal of the supernatant, the membrane pellet was stored at -80°C.
Receptor autoradiography was performed on 20-µm-thick cryostat (Leitz 1720, Rockleigh, NJ) sections of the membrane pellets, mounted on microscope slides and then stored at -20°C. 25 ]somatostatin 28 using increasing concentrations of the unlabeled peptide ranging from 0.1 to 1000 nM. As a control, somatostatin 28 was run in parallel using the same increasing concentrations. IC 50 values were calculated after quantification of the data using a computer-assisted image processing system as described previously (23 In]-DOTATOC were prepared with the methodology described in the previous section, without addition of cold metal but using lower peptide amounts. If necessary, radioligands were purified by SepPak C 18 cartridge and after evaporation of ethanol were diluted in NaCl (0.1% BSA, pH 7.4) to afford the very pure radioligands with a specific activity of ca. 40 GBq/µmol conjugate. The radiotracers were subjected to quality control by HPLC as described above.
Cell Culture. AR4-2J (ATCC, Manassas, VA) rat pancreatic tumor cells were cultured in Dulbecco's minimal essential medium (DMEM). DMEM was supplemented with vitamins, essential and nonessential amino acids, L-glutamine, antibiotics (peniciline/streptomycine), fungicide (amprotencine), and 10% fetal calf serum (FCS) as described elsewhere (25) .
Internalization/Externalization Studies. Internalization and externalization experiments were performed as indicated in previous publications in six-well plates (25, 26) . Briefly, the cells were washed twice with internalization medium [DMEM supplemented with 0.1% FCS, vitamins, essential and nonessential amino acids, L-glutamine, antibiotic (penicillin/streptomycin), and fungicide (amprotencin)], and they were allowed to adjust to the medium for 1 h at 37°C. Approximately 3.7 kBq (2.5 pmol) of radioligand were added to the medium, and the cells, 10 6 cells per well, were incubated (in triplicates) for 4 h at 37°C, 5% CO 2 , with or without excess cold octreotide (300 µL of a 1 µM solution) to determine nonspecific internalization. The final volume was 3 mL. At appropriate time periods, the internalization was stopped by removal of the medium and washing the cells with ice-cold phosphate-buffered saline. Cells were then treated with glycine buffer twice for 5 min at room temperature (0.05 M glycine solution, pH adjusted to 2.8 with 1 N HCl) to distinguish between cell surface-bound (acid releasable) and internalized (acid resistant) radioligand. Finally, cells were treated with 1 N NaOH and incubated at 37°C for 10 min to detach them from plates, and the radioactivity was measured in a γ-counter. For externalization the AR4-2J cells were allowed to internalize the radioligands for periods of 2 and 4 h and then were exposed to an acid wash, as described in the previous section, to dissociate cell-surface-receptor-bound radioligand. Three milliliters of culture medium were added to each well, cells were incubated at 37°C in a 5% CO 2 environment, and externalization of the cellincorporated radioactivity was studied during 3 h.
Biodistribution Experiments in AR4-2J TumorBearing Nude Mice. Six to ten week old Swiss female nude mice (IFFA-CREDO, France) were implanted subcutaneously with 5 million AR4-2J rat pancreatic tumor cells, previously expanded in Dulbecco's minimal essential medium (DMEM, GibcoBRL). DMEM was supplemented with vitamins, essential and nonessential amino acids, L-glutamine, antibiotics (penicilline/streptomycine), fungicide (amprotencine), and 10% fetal calf serum (FCS).
Fourteen days after inoculation, the tumors weighed 50-100 mg, and the mice were injected in the lateral tail vein with 5 µCi of [
67 Ga]-NODAGATOC or [ 111 In]-DOTATOC, diluted in NaCl (0.1% BSA, pH 7.4, total injected volume ) 200 µL). For determination of nonspecific uptake in tumor or receptor-positive organs, a group of four animals was injected in the tail vein with 50 µg of cold octreotide in NaCl (injected volume, 200 µL), 30 min before radiotracer injection. At 4, 24, and 48 h mice (in groups of three or four) were sacrificed and organs of interest collected, rinsed of excess blood, weighed, and counted in a γ-counter. The percentage of injected dose per gram (% ID/g) was calculated for each tissue. The total counts injected per animal were determined by extrapolation from counts of an aliquot taken from the injected solution. Urine samples were analyzed for possible metabolites by HPLC.
All animal experiments were performed in compliance with the Swiss regulation for animal treatment (Bundesamt fü r Veterinä rwesen, approval no. 789).
RESULTS

Synthesis and
Radiolabeling. An important step toward the synthesis of NOTA-derivatized bioactive peptides is the development of the corresponding prochelator NODAGA(tBu) 3 (6) (Scheme 1). The monoreactive NODAGA-prochelator was synthesized in five steps with an overall yield of 21% (Schemes 1 and 2). Two side reactions decreased the yields of steps 3 and 4. The monoalkylation of 1,4,7-triazacyclononane (1) with R-bromoglutaric acid 1-tert-butyl ester 5-benzyl ester (2) gave more than 20% of the dialkylated product 1,4-bis(1-carbobenzyloxy-3-carbo-tert-butoxypropyl)-1,4,7-triazacyclononane (3a) if the ratio of 1:2 was 2. Only the use of a 3-fold excess of 1 over 2 gave yields based on 2 of about 70% (Table 1 ). In step 4, overalkylation to a quarternary ammonium salt was found even if stoichiometric ratios were used. Therefore only 1.9 equiv of bromoacetic acid tert-butyl ester were employed. In addition, cooling to 4°C appeared to be advantageous to avoid overalkylation.
After these partially optimized synthetic steps, 6 was obtained in a reasonable overall yield of 21%. The linear side chain protected octapeptide D-Phe 1 -Cys(Acm)
-Tyr-(tBu)
3 -D-Trp(Boc) 4 -Lys(Boc) 5 -Thr(tBu) 6 -Cys(Acm) 7 -Thr-(ol)(tBu) 8 (7) was assembled on a TCP resin using Fmocstrategy (22) with DIC as coupling reagent. 6 (3 equiv) was coupled to 7 on the resin with the use of HATU (O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate) as coupling reagent. The protected peptide was mildly cleaved from the resin (20% CH 3 -COOH), cyclized with I 2 in methanol, deprotected, and purified by preparative HPLC analogous to Arano et al. (27) favor the 67 Ga 3+ over the metal impurities present. An expansion of this finding was outside the scope of this work.
Receptor Binding. Table 2 shows the newly synthesized NODAGATOC somatostatin analogues investigated and their respective IC 50 values for the five somatostatin receptor subtypes. As controls, somatostatin 28 (SS28), which binds with high affinity to all five somatostatin receptor subtypes, and our gold standards Ga/Y-DOTA-TOC were included. Ga-NODAGATOC shows high affinity only to sstr2 with an IC 50 of 3.5 ( 1.6 nM close to the one of Ga-DOTATOC (2.5 ( 0.5 nM) whereas it binds significantly better to sstr2 than Y-/In-DOTATOC. Measurable affinity was also found to sstr3 and sstr5. Interestingly, In-NODAGATOC binds with higher affinity to sstr2 (1.7 ( 0.2 nM) and also has distinctly higher affinity to sstr4/sstr5 than Ga-NODAGATOC. A remarkably low IC 50 value was found for sstr5, and no binding affinity was found to sstr1.
Stability of the Radiotracers. Our studies had demonstrated that with both radiolabeled peptides no radiolysis breakdown products were observed and that there is no appreciable release of 67 Ga even under extreme conditions (10 5 (28) . The two radioligands were internalized by AR4-2J cells in a time dependent way, as shown in Figure 2 . Both radiopeptides showed a fast and time dependent cell uptake by endocytosis which did not reach a plateau within 4 h of incubation at 37°C. There was no difference between the two radioligands. Both show about 18% (of the added activity) specific internalization after 2 h compared to only about 6% of [ 111 In]-DOTATOC (Figure 3) . Internalization was strongly reduced in the presence of 0.1 µM unlabeled octreotide (data not shown). In fact, nonspecific internalization was <3% of the added activity. The surface bound peptide (acid removable) was <7% of the added activity. The externalization of both peptides was studied with cells exposed 2 and/or 4 h to the radioligand as described for internalization (Figure 4) . Again a time dependent externalization was found which appears to depend somewhat on the time period cells were allowed to internalize as well as on the radioligand studied. Interestingly, the externalized radiopeptides were shown to be intact by HPLC as they coelute with the original radiopeptides.
Animal reported before (11, 25, 26, 28) and was used as a reference because a new batch of AR4-2J cells was used. Data obtained with nude mice bearing the AR4-2J pancreatic tumor are presented in Table 3 as % of injected dose per gram of tissue (% ID/g) as a function of time.
Both peptides displayed rapid blood clearance with only 0.05-0.07% ID/g remaining in blood at 4 h which can be associated with a fast elimination of radioactivity from the sstr-negative tissues not involved in the excretion process. In accordance with previous results (28) 67 Ga]-NODAGATOC shows high uptake values in sst receptor expressing organs such as adrenals, pancreas, and stomach, and in the AR4-2J tumor. In addition, a very rapid clearance from all other organs and tissues except the kidneys was found. The results of an in vivo competition experiment using large excess of octreotide preinjected iv resulted in a >83% reduction of tumor uptake and also in a reduction of the uptake in the sstr-positive organs (80% in pancreas, 82% in stomach, 76% in adrenals). The injection of the blocking dose had no significant influence on the uptake in nontarget organs except the kidneys where the uptake is increased by a factor of >2. ID/g vs 1.1 ( 0.25; stomach, 4.8 ( 0.67% ID/g vs 2.77 ( 0.75% ID/g; adrenals, 2.9 ( 0.43% ID/g vs 1.46 ( 0.35% ID/g). A further remarkable result of the new radiopeptide is the very favorable tumor:kidney ratio which is 3.0 at 4 h compared to 1 for 111 In-DOTATOC, the ratio even increases at 24 h to 5.7 whereas it remains 1 at 24 h for 111 In-DOTATOC. Additional tumor/unspecific tissue ratios at 4 h can be seen from Table 3 . They are as follows (in parentheses the data for 111 In-DOTATOC are given): 424 (188) for tumor/blood and 133 (54) for tumor/ liver. These very favorable ratios indicate the high potential of this radiopeptide for early time point, highly sensitive diagnostic tumor imaging. An unexpected result is the relatively quick washout from the tumor and receptor-positive organs. In the tumor, the dose dropped from 21.2% ID/g at 4 h to 2.6% ID/g at 24 h and 0.73% ID/g at 48 h. A similar rate of decline is found in the other receptor-positive organs. Somewhat fortunately, this decline is even faster in the kidneys. The residence time of 111 In-DOTATOC is distinctly longer in receptorpositive tissues but also in the kidneys.
DISCUSSION
In the past few years several SRIF-derived positronemitting radiopeptides have been developed (12, 13, (29) (30) (31) (32) , and some of them had been or are currently being investigated for PET imaging of SRIF receptor-positive tumors in patients (33) (34) (35) . An ideal PET tracer will allow to answer many important questions in the new and rising field of tumor targeting with use of radiopeptides, e.g., receptor regulation due to pharmacologic and chemotherapeutic intervention, receptor quantification and potential receptor downregulation due to receptor mediated radiopeptide therapy. The radiopeptides discussed in this manuscript were designed to answer questions arising from earlier developments in our laboratory and to offer new conjugates for studies with the Ga III , In III , and Cu II (36) radioisotopes. The macrocyclic chelator NOTA satisfies the coordination requirements of the respective metal ions in the indicated oxidation states. The NODAGATOC differs from our gold standard DOTA- [Tyr 3 ]-octreotide (DOTATOC) by the coupling of a new macrocyclic chelator to [tyr 3 ]-octreotide. We synthesized first a new bifunctional derivative of NOTA which had to fulfill two criteria:
(1) Compatibility with peptide synthesis; in other words, an orthogonally carboxylic acid group protected NOTA derivative has to be synthesized which upon specific deprotection of one carboxylic acid group is soluble in the common solvens used in solid-phase synthesis and may be used as an amino acid surrogate for coupling to the N-terminus of a requested peptide. (36) . Their syntheses used intra-or intermolecular cyclization strategy as key steps affording NOTA's functionalized on a carbon of the macrocyclic ring. They were not designed for coupling to peptides, and harsh conditions for deprotection and reduction were necessary. Our aim was to introduce the carboxy function for coupling on the methylene group of a carboxymethyl arm, allowing one to start with commercially available triaazacyclononane, thus avoiding a cyclization step. A similar strategy was used by Brechbiel et al. (39) to yield a bifunctional NOTA for antibody modification in 9% overall yield. In addition, this strategy was used in the functionalization of DOTA (21, (40) (41) . The key steps are the synthesis of an orthogonally protected bromoalkyl dicarboxylic acid diester and the monoalkylation of the triazacyclononane macrocycle. The latter step was performed using 3 equiv of 1,4,7-triazacyclononane over the alkylating diester to give 3 (69.2%). 5 was obtained in 90% yield using somewhat less than 2 equiv of bromoacetic acid tert-butyl ester to avoid overalkylation. The overall yield of the five steps was about 21%. The coupling of 6 to the linear octapeptide (appropriately protected) assembled on the TCP-resin was straightforward. The cleavage was followed by oxidative cyclization using I 2 and deprotection in a mixture of TFA/phenol/ thioanisole/water. The crude mixture was purified by preparative HPLC.
We have proposed earlier the use of a similar bifunctional chelator (NODASA ) 1,4,7-triazacyclononane-1-succinic acid-4,7-diacetic acid) and the use of the radiogallium complex in a prelabeling approach (42) . Although this approach is very attractive and was proven to work well with model peptides and with the nonradioactive Ga III , it proved not to be practical for larger amounts of radioactivity because of relatively low coupling yields of [ 67 Ga]-NODASA to the peptide due to low solubility. This caused a large waste of radioactivity. The coupling of the present prochelator works well under peptide synthesis conditions and allows the preparation of a kit-formulated version of the conjugate.
Receptor Binding Studies. One of the aims of this study was to probe the hypothesis that the higher sstr2 affinity of [ (42, 44) . In this context, it is interesting to note that in the solid-state In III -NOTA is crystallizing with one Cl -ion in a pentagonal bipyramidal coordination environment (44) . We propose as a possible explanation of the above-mentioned affinity differences that in the biological fluids used in our assays either with regard to radiometal transfer. The 67 Ga-labeled peptide is >10 3 times more stable than [ 111 In]-NODA-GATOC which correlates well with the thermodynamic stability of most of the triaza complexes of these two metals (e.g., log K (GaNOTA) ) 30.98, log K (InNOTA) ) 25.9 (45) . Also, the metabolic stability is very high in fresh human serum and surprisingly in a rat liver homogenate (data not shown).
Cell Uptake and Release. The internalization and release of the two new radiopeptides was studied in the AR4-2J cell line known to express sstr2 receptors (28) . The cell uptake at 4 h was the same for both radiopeptides but was a factor of 3 higher than for [
111 In]-DOTATOC at 2 h (18% vs about 6%). The fast internalization indicates thatsaccording to the current knowledge that only agonistic drugs can internalize (46) In the time interval of the study (30 min to 4 h) no steady state was reached yet but the distinct leveling-off indicates the close approach to it which can be explained with the beginning efflux.
If the cells upon internalization of the radioligand for 2 and/or 4 h were exposed to the culture medium, again a time-dependent efflux of the radiopeptides could be observed, indicating a rapid recycling of the radiopeptides to the extracellular medium. A steady state is reached already after 2-4 h of release studies. This is due to the reactivation of the receptor by the released radiopeptide which was shown to be intact by HPLC as it coelutes with the original radiopeptides. It appears that already 25-40% of the externalized agonist are enough to stimulate the receptor to undergo reendocytosis. At steady state, about 60-75% of the radioactivity are located inside the cell and can be routed to lysosomes for degradation. The finding that the amount of externalized radiopeptide and the earlier reaching of a steady state appear to depend on the time internalization was allowed ( Figure 3 ) indicates that this mechanism may be valid. On the other hand, it may just reflect that the steady state is reached earlier because the absolute value of 4 h internalization is higher than the one of 2 h internalization. A distinction between the two possibilities can only be made after careful structural analysis of the peptide contained inside the cells. The interpretation above is in keeping with the conclusion of data obtained by Koenig 67 Ga]-DOTATOC (data published earlier) the new tracer shows almost the same performance, i.e., a somewhat lower tumor uptake but a higher tumor-to-blood, tumor-to-liver, tumor-to-heart, and a comparable tumor-to-kidney ratio.
In addition, using the same animal model it is far superior to 111 In-DTPA-octreotide which showed only 3.03% ( 0.26% ID/g in the tumor at 4 h and an inferior tumor-to-normal organ ratio, e.g. tumor/blood ) 7.6, tumor/liver ) 4 at the same time point (28) .
Unforeseen is the fast washout (short residence time) of the tumor and sstr2-positive organs. It is faster compared to other somatostatin-based radiopeptides studied in this laboratory. The approximate biological half-life in the tumor is 7 h. The reason for this is not known yet. Our original hypothesis that it is due to metabolic instability of the exposed peptide bond between NODAGA and D-Phe due to the coupling via the carboxy ethyl spacer compared to the DOTA monoamide coupled peptides was not confirmed by studies with liver homogenate and fresh serum. In the latter cases a protection of the same bond is accomplished due to the fact that the amidocarboxy oxygen is involved in the coordination to the metal. The short tumor retention time resembles somewhat the behavior of most of the [
64 Cu]-TETA-SRIF analogues discussed by Lewis et al. (48) . Also, as discussed above, internalization and release studies do not give any clue as to the reason for the fast washout.
In conclusion, NODAGATOC most likely is a peptidechelator conjugate with very promising properties for human studies if labeled with the short-lived positron emitters 68 Ga and 66 Ga. Because of the relatively fast washout from tumors, its suitability for a potential therapeutic application with the Auger electron emitter 67 Ga has to be shown in other animal models and in patients.
In addition, we developed a new chelator-somatostatin analogue for selective tumor targeting which is also suitable for
111
In and because of favorable complex stability most likely for 64 Cu and 55 Co labeling and their use in the targeting of sstr2-positive tumors in patients.
